Design and discovery of novel quinazolinedione-based redox modulators as therapies for pancreatic cancer.
Biochim Biophys Acta
; 1840(1): 332-43, 2014 Jan.
Article
en En
| MEDLINE
| ID: mdl-23954204
Palabras clave
1,5-bis{[2-(di-methylamino) ethyl]amino}-4,8-dihydroxyanthracene-9,10-dione; 3-Nitrooxyphenyl acetylsalicylate; 5-chloromethylfluorescein diacetate; Anticancer compounds; CMFDA; DMEM; DMSO; DNA; DPBS; DRAQ5®; Dulbecco's Modified Eagle Medium; Dulbecco's Phosphate Buffered Saline; EDTA; FoxO3a; GAPDH; GSH; JNK; MnSOD; N-acetylcysteine; NAC; NAD(P)H dehydrogenase (quinone) 1; NADPH; NADPH oxidase; NO-ASA; NOX1; NQO1; OCR; Oxidative stress in cancer cells; RIPA buffer; ROS; ROS-mediated cell death; RPMI-1640; Radio-Immunoprecipitation Assay buffer; Redox regulation; Roswell Park Memorial Institute-1640; Small molecule drug discovery; c-Jun N-terminal kinase; deoxyribonucleic acid; dimethyl sulfoxide; ethylene diaminetetraacetic acid; forkhead box transcription factor 3a; glutathione (reduced); glyceraldehyde 3-phosphate dehydrogenase; manganese superoxide dismutase, MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; nicotinamide adenine dinucleotide phosphate (reduced); oxygen consumption rate; reactive oxygen species
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias Pancreáticas
/
Diseño de Fármacos
/
Apoptosis
/
Estrés Oxidativo
/
Metabolismo Energético
/
Quinazolinonas
Tipo de estudio:
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Biochim Biophys Acta
Año:
2014
Tipo del documento:
Article
País de afiliación:
Estados Unidos